MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Eli Lilly, Johnson & Johnson and Pfizer helped drug developer TRexBio close its $59m series A round while Slack backed human resources software provider Oyster at a $475m valuation.

Theodorus has contributed to a $23.8m series A round for NeuVasQ, the neurological disease drug developer spun out of Université libre de Bruxelles.

Wake Forest University spinout Renovo closed the round at $6.4m and will put the funding into further development of its brain injury treatment system.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

With co-founders from Stanford University and National University of Singapore, Nuevocor aims to develop gene therapies for cardiomyopathies.

Behavioural health platform developer Brightline captured $72m in a round led by GV, while Gopuff is set to buy Siemens and ST-backed mobility software producer RideOS.

Alexandria Venture Investments was among the participants in a series A for the cellular cancer therapeutics developer based on work at Institut Curie and Memorial Sloan Kettering.

Alexandria Venture Investments was among the participants in a series A round for the cellular cancer therapeutics developer.